In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Lipocine Inc.. Trade Record

NASDAQ:LPCN Lipocine Inc. stock gains 57.44% Exit Sep 11, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart LPCN Aug 12, 2019, priceSeries
About Lipocine Inc.

Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The company's pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which has completed Phase 2 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Trade Information
Trade Type
LONG
ReliabilityScore™
92.21
Entry Date
Aug 12, 2019
Entry Price
1.90
Sell Date
Sep 11, 2019
Sell Price
2.99
Net Gain
57.44%
Hold Time
21 Trading Days